---
title: "AD-Smart trial to repurpose diabetes and ADHD drugs for Alzheimer’s patients"
id: "bmj-0-ad-smart-alzheimer-x2019-s-trial-will-test-diabetes-and-adhd-drugs-on-patients"
canonical_url: "https://medichelpline.com/clinical-feed/bmj-0-ad-smart-alzheimer-x2019-s-trial-will-test-diabetes-and-adhd-drugs-on-patients"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "BMJ"
source_url: "http://www.bmj.com/content/395/bmj-2026-101219.short?rss=1"
published_at: "2026-10-22T14:21:17.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# AD-Smart trial to repurpose diabetes and ADHD drugs for Alzheimer’s patients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-0-ad-smart-alzheimer-x2019-s-trial-will-test-diabetes-and-adhd-drugs-on-patients
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** BMJ
- **Source URL:** [Original Journal Publication](http://www.bmj.com/content/395/bmj-2026-101219.short?rss=1)
- **Published At:** 2026-10-22T14:21:17.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- A UK clinical trial named **AD-Smart** has been launched to evaluate multiple repurposed drugs simultaneously as potential treatments for **Alzheimer’s disease**. - The trial will start by testing two existing medicines currently licensed for **type 2 diabetes** and **ADHD**, investigators reported. - The primary objectives, as described in the source, are to determine whether the medicines can reduce cognitive symptoms (memory and thinking problems) and help maintain patients’ quality of life. - The study team designed the trial to accelerate therapeutic development by using a multi-arm adaptive randomised approach (the source named the acronym but did not provide the protocol details). - The BMJ item noted that about 600,000 people in the UK have Alzheimer’s, and NHS England has met a dementia diagnosis target of 66.7% for people over 65 for the first time since March 2020, data published the same day indicated. - The article reiterated that current NHS treatments do not slow or stop Alzheimer’s; available medicines address symptoms only. - The source did not report specific trial methodology elements—such as dosing, eligibility criteria, sample size, primary or secondary endpoints, randomisation ratios, or timelines—so those details remain unspecified in this report. - The piece framed AD-Smart as an effort to shorten the time needed to identify effective therapies by testing multiple candidate drugs in parallel, but it did not disclose regulatory milestones or anticipated completion dates.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1#main-content) Intended for healthcare professionals * [Subscribe](https://www.bmj.com/us/subscribe) * [ My Account ](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1) * [My email alerts](https://myaccount.bmj.com/myaccount/account/hw-registration.html) * [BMA member login](https://bmjverification.bma.org.uk/validate/userdetails?url=https://www.bmj.com/content/395/bmj-2026-101219?rss=1&variant=short&sso=) [ Login ](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1) * Username * Password * [Forgot your log in details?](https://www.bmj.com/user/password "Retrieve your credentials.") [Need to activate](https://journals.bmj.com/cgi/activate/basic) * * * [BMA Member Log In](https://bmjverification.bma.org.uk/validate/userdetails?url=https%3A//www.bmj.com/content/395/bmj-2026-101219%3Frss%3D1%26variant%3Dshort%26sso%3D "Log in here if you are a BMA member.") [Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&subcode=bmjjournals&hw-shib-return-uri=https%253A%252F%252Fwww.bmj.com%252Fcontent%252F395%252Fbmj-2026-101219.short%253Frss%253D1) [Log in via your institution](https://www.bmj.com/login/shibboleth?uri=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F395%2Fbmj-2026-101219%3Frss%3D1&subcode=bmjjournals&env=prod) Edition: [ US ](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1) * [UK](https://www.bmj.com/bmj_countries/switch/uk?destination=node/1129244%3Frss%3D1%26variant%3Dshort) * [South Asia](https://www.bmj.com/bmj_countries/switch/india?destination=node/1129244%3Frss%3D1%26variant%3Dshort) * [International](https://www.bmj.com/bmj_countries/switch/international?destination=node/1129244%3Frss%3D1%26variant%3Dshort) [Our company](https://www.bmj.com/company?int_source=tbmj&int_medium=header&int_campaign=URLswitch) [ Toggle navigation ](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1) [ The BMJ logo ](https://www.bmj.com/ "Home") [Site map](https://www.bmj.com/sitemap) [Search](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1 "Search") ## Search form Search Search * [Advanced search](https://www.bmj.com/search/advanced "Advanced search") * [Search responses](https://www.bmj.com/rapid-responses "Search responses") * [Search blogs](https://blogs.bmj.com/bmj/ "Search blogs") [ Toggle top menu ](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1) * [Research](https://www.bmj.com/us/research) * [At a glance](https://www.bmj.com/us/research) * [Research papers](https://www.bmj.com/us/research/research) * [Research methods and reporting](https://www.bmj.com/us/research/research%20methods%20%26amp%3B%20reporting) * [Minerva](https://www.bmj.com/us/research/minerva) * [Education](https://www.bmj.com/us/education) * [At a glance](https://www.bmj.com/us/education) * [Clinical reviews](https://www.bmj.com/us/education/clinical%20review) * [Practice](https://www.bmj.com/us/education/practice) * [Minerva](https://www.bmj.com/us/education/minerva) * [Endgames](https://www.bmj.com/us/education/endgames) * [State of the art](https://www.bmj.com/specialties/state-art) * [What your patient is thinking](https://www.bmj.com/specialties/what-your-patient-thinking) * [Rapid recommendations](https://www.bmj.com/rapid-recommendations) * [Student](https://www.bmj.com/student) * [News & Views](https://www.bmj.com/us/news) * [At a glance](https://www.bmj.com/us/news) * [News](https://www.bmj.com/us/news/news?category=News) * [Features](https://www.bmj.com/us/news/feature) * [Editorials](https://www.bmj.com/us/news/editorial) * [Analysis](https://www.bmj.com/us/news/analysis) * [Opinion](https://www.bmj.com/news/opinion) * [Head to head](https://www.bmj.com/us/news/head%20to%20head) * [Editor's choice](https://www.bmj.com/us/news/editor%27s%20choice) * [Letters](https://www.bmj.com/us/news/letter) * [Obituaries](https://www.bmj.com/us/news/obituary) * [Careers](https://www.bmj.com/careers-articles) * [Rapid responses](https://www.bmj.com/rapid-responses) * [Campaigns](https://www.bmj.com/campaigns) * [At a glance](https://www.bmj.com/campaigns) * [Better evidence](https://www.bmj.com/better-evidence) * [Climate change](https://www.bmj.com/campaign/climate-emergency) * [Divestment from fossil fuels](https://www.bmj.com/divestment) * [Patient and public partnership](https://www.bmj.com/campaign/patient-partnership) * [Too much medicine](https://www.bmj.com/too-much-medicine) * [Wellbeing](https://www.bmj.com/wellbeing) * [The BMJ Collections](https://www.bmj.com/content/bmj-collections) * [Jobs](https://www.bmj.com/careers) * [Doctor Jobs UK](https://www.bmj.com/careers) * [Hospital Jobs UK](https://www.bmj.com/careers/jobs/hospital/) * [GP Jobs UK](https://www.bmj.com/careers/jobs/general-practice/) * [International Jobs](https://www.bmj.com/careers/jobs/international/) * [Archive](https://www.bmj.com/archive) * [For authors](https://www.bmj.com/about-bmj/resources-authors) * [Hosted](http://hosted.bmj.com) 1. [News & Views](https://www.bmj.com/us/news) 2. AD-Smart: Alzheimer’s... 3. AD-Smart: Alzheimer’s trial will test diabetes and ADHD drugs on patients News # AD-Smart: Alzheimer’s trial will test diabetes and ADHD drugs on patients BMJ 2026; 395 doi: (Published 22 October 2026) Cite this as: BMJ 2026;395:e101219 * [Article](https://www.bmj.com/content/395/bmj-2026-101219 "Article Tab - Article")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_art/node:1129244/1 "Article Tab - Article") * [Related content](https://www.bmj.com/content/395/bmj-2026-101219/related "Article Tab - Related Articles")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_related_art/node:1129244/1 "Article Tab - Related Articles") * [Metrics](https://www.bmj.com/content/395/bmj-2026-101219/article-info "Article Tab - Info & Metrics")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_info/node:1129244/1 "Article Tab - Info & Metrics") * [Responses](https://www.bmj.com/content/395/bmj-2026-101219/rapid-responses "BMJ Article Related Rapid Responses")[](https://www.bmj.com/panels_ajax_tab/bmj_related_rapid_responses/node:1129244/1 "BMJ Article Related Rapid Responses") * [Peer review](https://www.bmj.com/content/395/bmj-2026-101219/peer-review "Article Tab - Peer review")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_peer_review/node:1129244/1 "Article Tab - Peer review") * [](https://www.bmj.com/content/395/bmj-2026-101219/submit-a-rapid-response "BMJ Rapid Responses Form")[](https://www.bmj.com/panels_ajax_tab/bmj_rapid_responses_form/node:1129244/1 "BMJ Rapid Responses Form") ![Loading](https://www.bmj.com/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) 1. [Gareth Iacobucci](https://www.bmj.com/about-bmj/editorial-staff/gareth-iacobucci "Gareth Iacobucci") [Author affiliations](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1) 1. The BMJ A new clinical trial has been launched in the UK that researchers hope will cut years from the search for treatments for Alzheimer’s disease. The study will test multiple drugs simultaneously, starting with two repurposed medicines already used to treat type 2 diabetes and attention deficit/hyperactivity disorder (ADHD). It will examine whether the medicines can lessen symptoms such as memory and thinking problems and help people maintain their quality of life. Alzheimer’s is the most common type of dementia, affecting around 600 000 people in the UK. Data published today show that the NHS in England met its target to diagnose dementia in at least 66.7% of the patients over 65 who are estimated to have dementia for the first time since March 2020.1 No current NHS treatments can slow or stop Alzheimer’s, although medicines can be used to manage its symptoms.2 The AD-Smart trial (Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial) aims to accelerate the development of new treatments.3 ## What is the AD-Smart trial? The study … [View Full Text](https://www.bmj.com/content/395/bmj-2026-101219.full) ## Log in ### Log in using your username and password [BMA Member Log In](https://bmjverification.bma.org.uk/validate/userdetails?url=https%3A//www.bmj.com/content/395/bmj-2026-101219%3Frss%3D1%26variant%3Dshort%26sso%3D "Log in here if you are a BMA member.") If you have a subscription to The BMJ, log in: Username * Password * [Forgot your log in details?](https://www.bmj.com/user/password "Retrieve your credentials.") * [Need to activate](https://journals.bmj.com/cgi/activate/basic) * [Log in via institution](https://www.bmj.com/login/shibboleth?uri=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F395%2Fbmj-2026-101219%3Frss%3D1&subcode=bmjjournals&env=prod) * [Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&subcode=bmjjournals&hw-shib-return-uri=https%253A%252F%252Fwww.bmj.com%252Fcontent%252F395%252Fbmj-2026-101219.short%253Frss%253D1) ### Log in through your institution ## Subscribe from £184 * Subscribe and get access to all BMJ articles, and much more. [Subscribe](https://www.bmj.com/us/subscribe) * For online subscription **Access this article for 1 day for: £50 / $60/ €56** ([excludes VAT](https://www.bmj.com/company/eu-vat-rates/)) You can download a PDF version for your personal record. [Buy this article](https://www.bmj.com/highwire/payment/ppv/1129244) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.bmj.com/content/395/bmj-2026-101219&count=horizontal&via=&text=AD-Smart%3A%20Alzheimer%E2%80%99s%20trial%20will%20test%20diabetes%20and%20ADHD%20drugs%20on%20patients&counturl=www.bmj.com/content/395/bmj-2026-101219 "Tweet This") ## Article tools [PDF](https://www.bmj.com/content/395/bmj-2026-101219.full.pdf "PDF")[0 responses](https://www.bmj.com/content/395/bmj-2026-101219/rapid-responses) * [Respond to this article](https://www.bmj.com/content/395/bmj-2026-101219/submit-a-rapid-response) * [Print](https://www.bmj.com/content/395/bmj-2026-101219.full-text.print) * [Alerts & updates](https://www.bmj.com/#mini-panel-jnl-bmj-article-page-alerts-1) #### Article alerts Please note: your email address is provided to the journal, which may use this information for marketing purposes. #### Log in or register: Username * Password * [Register for alerts](https://myaccount.bmj.com/myaccount/registration.html?regService=bmj-registration&fwdUrl=https://www.bmj.com/content/395/bmj-2026-101219?tab=article-alert&itemId=pr1906) If you have registered for alerts, you should use your registered email address as your username * [Citation tools](https://www.bmj.com/#mini-panel-article-page-citation-download-1) #### Download this article to citation manager Gareth Iacobucci Iacobucci G. AD-Smart: Alzheimer’s trial will test diabetes and ADHD drugs on patients BMJ 2026; 395 :e101219 doi:10.1136/bmj-2026-101219 * BibTeX (win & mac)[Download](https://www.bmj.com/highwire/citation/1129244/bibtext) * EndNote (tagged)[Download](https://www.bmj.com/highwire/citation/1129244/endnote-tagged) * EndNote 8 (xml)[Download](https://www.bmj.com/highwire/citation/1129244/endnote-8-xml) * RefWorks Tagged (win & mac)[Download](https://www.bmj.com/highwire/citation/1129244/refworks-tagged) * RIS (win only)[Download](https://www.bmj.com/highwire/citation/1129244/ris) * Medlars[Download](https://www.bmj.com/highwire/citation/1129244/medlars) ## Help If you are unable to import citations, please contact technical support for your product directly (links go to external sites): * [EndNote](http://www.endnote.com/support/ensupport.asp) * [ProCite](http://www.procite.com/support/pcsupport.asp) * [Reference Manager](http://www.refman.com/support/rmsupport.asp) * [RefWorks](http://www.refworks.com/content/products/content.asp) * [Zotero](http://www.zotero.org/support) * [Request permissions](https://s100.copyright.com/AppDispatchServlet?publisherName=BMJ&publication=bmj&title=AD-Smart%3A%20Alzheimer%E2%80%99s%20trial%20will%20test%20diabetes%20and%20ADHD%20drugs%20on%20patients&publicationDate=10/22/2026&author=Gareth%20Iacobucci&contentID=10.1136/bmj-2026-101219&volumeNum=395&issueNum=&startPage=&endPage=&copyright=BMJ%20Publishing%20Group%20Ltd&oa=n&orderBeanReset=1&link_type=PERMISSIONDIRECT&atom=/bmj/395/bmj-2026-101219.atom) * [Author citation](https://www.bmj.com/#mini-panel-jnl-bmj-article-page-citation) * [Articles by Gareth Iacobucci](https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term=Iacobucci%20Gareth%5Bau%5D&dispmax=50) * [Add article to BMJ Portfolio](https://portfolio.bmj.com/portfolio/add-to-portfolio.html?t=AD-Smart%3A%20Alzheimer%E2%80%99s%20trial%20will%20test%20diabetes%20and%20ADHD%20drugs%20on%20patients&u=https%3A//www.bmj.com/content/395/bmj-2026-101219) [Email to a friend](https://www.bmj.com/#mini-panel-jnl-bmj-article-button-email-to-1) #### Forward this page Thank you for your interest in spreading the word about The BMJ. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following [AD-Smart: Alzheimer’s trial will test diabetes and ADHD drugs on patients](https://www.bmj.com/content/395/bmj-2026-101219) Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. [ ![Article has an altmetric score of 1](https://badges.altmetric.com/?size=240&score=1&types=tttttttt) ](https://www.altmetric.com/details.php?domain=www.bmj.com&citation_id=206917431) [See more details](https://www.altmetric.com/details.php?domain=www.bmj.com&citation_id=206917431) [ Posted by **2** X users ](https://www.altmetric.com/details.php?domain=www.bmj.com&citation_id=206917431&tab=twitter) ![](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg) ## This week's poll Should medical students be encouraged to use generative artificial intelligence to study? Yes No Vote[View Results](javascript:PD_vote58250\(1\);) [Read](https://www.bmj.com/content/390/bmj.r1418) related article [See](https://www.bmj.com/about-bmj/poll-archive) previous polls [ Back to top](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1#page) ## Follow us on * [X](https://x.com/bmj_latest) * [Facebook](https://www.facebook.com/bmjdotcom) * [Instagram](https://www.instagram.com/the_bmj_) * [Linkedin](https://www.linkedin.com/showcase/the-bmj/) * [YouTube](http://youtube.com/user/BMJmedia) * [RSS](http://feeds.bmj.com/bmj/recent) ## Content links * [Collections](http://www.bmj.com/collections) * [Health in South Asia](http://www.bmj.com/health-in-south-asia) * [Women’s, children’s & adolescents’ health](http://www.bmj.com/content/women%E2%80%99s-children%E2%80%99s-and-adolescents%E2%80%99-health-0) * [Zika virus](http://www.bmj.com/freezikaresources) * [Research](https://www.bmj.com/us/research) * [Education](https://www.bmj.com/us/education) * [News and views](https://www.bmj.com/us/news) * [BMJ Opinion](http://blogs.bmj.com/bmj/) * [Rapid responses](https://www.bmj.com/rapid-responses) * [Archive](https://www.bmj.com/archive) ## About us * [About us](https://www.bmj.com/about-bmj) * [Editorial staff](https://www.bmj.com/about-bmj/editorial-staff) * [BMJ in the USA](https://www.bmj.com/about-bmj/editorial-staff/bmj-united-states) * [BMJ in Latin America](https://www.bmj.com/health-in-latin-america) * [BMJ in South Asia](https://www.bmj.com/about-bmj/editorial-staff/bmj-south-asia) * [Advisers](https://www.bmj.com/about-bmj/advisory-panels) * [Policies](https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists) * [Submit your paper](http://mc.manuscriptcentral.com/bmj) ## Resources * [Authors](https://www.bmj.com/about-bmj/resources-authors) * [Reviewers](https://www.bmj.com/about-bmj/resources-reviewers) * [BMA members](https://www.bmj.com/about-bmj/resources-bma-members) * [Readers](https://www.bmj.com/about-bmj/resources-readers) * [Subscribers](https://www.bmj.com/about-bmj/resources-subscribers) * [Advertisers and sponsors](https://www.bmj.com/about-bmj/resources-advertisers-and-sponsors) * [Media](https://www.bmj.com/about-bmj/resources-media) * [Recruiters](https://recruiter.bmj.com/) ## Explore BMJ * [Our company](https://www.bmj.com/company/?int_source=tbmj&int_medium=footer&int_campaign=URLswitch) * [BMJ Careers](https://jobs.bmj.com/) * [BMJ Learning](http://learning.bmj.com/) * [BMJ Masterclasses](http://masterclasses.bmj.com) * [BMJ Journals](http://journals.bmj.com) * [BMJ Student](https://www.bmj.com/student) * [Academic edition of The BMJ](http://www.bmj.com/about-bmj/resources-readers) * [BMJ Best Practice](http://bestpractice.bmj.com/) * [The BMJ Awards](http://thebmjawards.bmj.com/home) ## My account * [Email alerts](http://myaccount.bmj.com/myaccount/account/hw-registration.html) * [Activate subscription](http://journals.bmj.com/cgi/activate) ## Information * [Contact us](https://www.bmj.com/about-bmj/contact-us) * [Complaints](https://www.bmj.com/about-bmj/complaints-procedure) * [Accessibility](https://journals.bmj.com/our-journals/accessibility-tbmj/) * Cookie settings * [Cookie Policy](https://bmjgroup.com/cookie-notice-at-bmj-group/) * [Privacy policy](https://bmjgroup.com/privacy-notice/) * [Website T&Cs](https://bmjgroup.com/website-terms-and-conditions/) * [Revenue Sources](http://group.bmj.com/group/about/revenue-sources) * [HighWire Press](http://home.highwire.org/) * [Sitemap](https://www.bmj.com/sitemap) * [Legal Information](https://bmjgroup.com/legal-information/) Copyright © 2026 BMJ Publishing Group Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved. ## Cookies and privacy We and our 381 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under we and our partners process data to provide. Selecting Reject All or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie settings link on the bottom of the webpage. Your choices will have effect within our Website. For more details, refer to our Privacy Policy.[Cookie policy](https://www.bmj.com/company/legal-information/bmj-cookie-policy/) ### We and our partners process data to provide: Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development. [ List of Partners (vendors) ](https://www.bmj.com/content/395/bmj-2026-101219.short?rss=1) I Accept Reject All Manage preferences ![Company Logo](https://cookie-cdn.cookiepro.com/logos/static/ot_company_logo.png) ## About Your Privacy ## About Your Privacy * ### Your Privacy * ### Strictly Necessary Cookies * ### Performance Cookies * ### Functional Cookies * ### Targeting Cookies * ### Google & IAB TCF 2 Purposes of Processing * ### Store and/or access information on a device 295 partners can use this purpose * ### Personalised advertising and content, adver
## Related Clinical Research

- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)
- [Sex differences in genetic links between modifiable risk factors and Alzheimer’s disease](https://medichelpline.com/clinical-feed/medrxiv-15-sex-differences-in-genetic-liability-to-modifiable-alzheimer-s-disease-risk.md)
- [Education and Alzheimer’s Genetic Risk Do Not Explain GLP-1 RA Associations With Dementia in Type](https://medichelpline.com/clinical-feed/medrxiv-23-education-and-alzheimer-disease-genetic-risk-in-associations-of-glp-1-receptor.md)
- [Higher systemic GLP1R expression linked to lower Parkinson’s risk in GLP-1RA–treated type 2 diabet](https://medichelpline.com/clinical-feed/pubmed-41967915.md) (DOI: 10.1093/brain/awag130)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.